



For Immediate Release

**RoverMed BioSciences, Inc. Selected as a
Minnesota Business “Most Likely to Succeed” Finalist**

RoverMed now competes against three other MedTech companies for the top honor in their category

Minneapolis, MN (08/18/17) – St. Cloud based bioscience startup RoverMed BioSciences has been named a finalist in the *Medical Technology* category of *Minnesota Business Magazine’s* “Most Likely to Succeed” competition. Finalists were chosen by readers from a larger list of start-ups and will now be considered by *Minnesota Business* staff, who will determine the winner.

“It’s an honor to see RoverMed’s technology, leadership team and business model recognized by *Minnesota Business* readers amongst this state’s robust and auspicious medical technology community,” said Laura Brod, CEO of RoverMed. “We are seeing great traction in our company and we believe that our leading nanocrystal drug delivery system will succeed in changing the way we treat some of the most challenging medical conditions we face today. We have proven that RoverMed’s novel ultra-small nanocrystal technology is capable of reaching the most difficult disease sites for drug delivery and we are excited to advance how precision targeted drug delivery systems like ours can potentially transform patient outcomes for the better.”

And, as the only female-led business competing in their category, RoverMed appreciates the opportunity to represent Minnesota’s MedTech start-up community. Winners of the “Most Likely to Succeed” competition will be announced in the November edition of *Minnesota Business*.

About RoverMed

Minneapolis-based RoverMed’s Crystalline Ultra-Small Particle (CUSP) is the leading nanocapsule technology capable of cell specific delivery of biologic drugs directly to the nucleus of disease cells to deliver precision targeted treatments for challenging diseases. RoverMed’s technology carries medication beyond the human liver, and exclusively into the nuclei of targeted cells – no matter where those cells are located in the body. The company’s technology is designed to achieve unequalled delivery efficiency, precision targeting, and effectiveness.

Media Contact: Jing Zhang
Media Email: jing@ainsleyshea.com
Media Phone: 651-414-1095